Aspen Neuroscience’s autologous, personalised stem cell therapy is set for a pivotal trial after it showed improved "ON" and "OFF" time in Parkinson’s disease patients. Data from the first eight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results